Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

GuideUpdated 10 min read

How to get peptides prescribed legally in 2026

Which peptides a licensed prescriber can lawfully write for today, which are neither approved nor 503A eligible, how telehealth rules work, and the red flags that mean a product is not a prescription.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: a licensed prescriber can lawfully prescribe any FDA-approved peptide drug, such as tesamorelin, tirzepatide, semaglutide, or bremelanotide. [1] [2] [3] [4] A compounding pharmacy can fill a narrower set of peptides that meet the federal compounding rules. Most of the healing, "anti-aging," and muscle peptides sold online meet none of those conditions today, so no prescription makes them lawful. For six of them, including BPC-157, HHS released a draft policy in October 2026 that describes when it does not intend to take enforcement action; see what the HHS peptide policy changed.

This guide explains which peptides fall into which group, where the July 2026 FDA advisory meeting and HHS's October 2026 draft policy leave BPC-157 and similar peptides, how telehealth fits in, and what a legitimate visit looks like. It does not give doses or protocols. If you are new to the topic, start with what peptide therapy is.

Which peptides can a doctor legally prescribe today?

There are two lawful routes, and a peptide has to fit one of them.

Route 1: an FDA-approved drug. A prescriber may write for an approved drug for its labeled use and, using medical judgment, off label. The approved peptides most often asked about are:

  • Tirzepatide and semaglutide for chronic weight management and related conditions, as Zepbound and Wegovy. [2] [3]
  • Tesamorelin as Egrifta, approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. [1] Our HIV lipodystrophy page covers that indication.
  • Bremelanotide (PT-141) as Vyleesi, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. [4]

Route 2: a lawfully compounded peptide. Under section 503A, a state-licensed pharmacy may compound for an individual patient with a prescription, using a bulk ingredient only if it is a component of an approved drug, has a USP or NF monograph, or appears on FDA's 503A bulks list. [5] Compounded drugs are not FDA approved, and FDA does not review them before they are sold. [6]

Biologics are the exception to route 2. Among the peptides clinics most often sell for body composition, tesamorelin fits route 1 only: it is an approved drug, but tesamorelin is a biologic: Egrifta moved to a biologics license (BLA 022505) on March 23, 2020, and FDA states that biological products are not eligible for the 503A or 503B compounding exemptions, so compounded tesamorelin has no lawful basis. [6] [20] Egrifta WR by prescription is the only lawful product; see tesamorelin cost and our tesamorelin prescription guide.

Sermorelin is a gray zone. Its brand, Geref, was discontinued, and FDA later found it was not withdrawn for safety or effectiveness reasons. [12] Many 503A pharmacies compound it on the basis of that former approval; whether that holds up depends on the pharmacy and its state board. The sermorelin vs tesamorelin comparison covers both.

Where do BPC-157 and the other advisory committee peptides stand?

In April 2026 FDA moved a group of peptides off Category 2, its list of bulk substances that raise significant safety concerns, to a list of nominations withdrawn by their nominators, which leaves them in no 503A category. [9] On July 23 to 24, 2026, FDA presented seven of them to its Pharmacy Compounding Advisory Committee (PCAC), and its own briefing recommended against adding any to the 503A bulks list. [10] For six of them, BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon, HHS's policy (Appendix B) says FDA's drug center recommended against listing and the advisory committee voted in favor. [32]

A committee vote is not a rule. A substance joins the bulks list only through notice-and-comment rulemaking and a final rule, the process FDA used for its first bulks-list rule in 2019. [8] FDA has proposed no rule, and none of the six is on the list. [7]

On October 28, 2026, HHS released a draft enforcement discretion policy for those six. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds one of them when every condition is met: a single-ingredient product, an allowed route for that peptide, a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a tested certificate of analysis, and reporting of serious adverse events to FDA. [31] [32] It is not an FDA approval, does not add anything to the bulks list, is not binding, and HHS may revisit it. The notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. [31] Blends and stacks are not covered, research-use-only products sold for human use are still unlawful, and state law still applies. [32] Our explainer on the HHS peptide policy lists the route limits for each peptide.

Even bulks-list status would change only one thing: a licensed 503A pharmacy could compound it for an individual patient with a prescription. It would not make the peptide an approved drug, would not create an approved dose, and would not open 503B outsourcing, which runs on a separate list. [11] The evidence would also be unchanged; BPC-157, for example, is still graded animal only. Track each step on the BPC-157 regulatory tracker and the full regulatory feed.

Which peptides are neither approved nor on the bulks list?

CJC-1295, ipamorelin, selank, thymosin alpha-1, injectable GHK-Cu, 5-amino-1MQ, and melanotan II are not approved drugs and are not on the 503A bulks list. [7] No prescription changes that. Several are offered anyway: FDA has warned a state-licensed 503A pharmacy that compounded CJC-1295, ipamorelin, selank, and melanotan II outside section 503A. [26] What's actually offered, below, covers what that means for you. Blends inherit their strictest ingredient, so a CJC-1295 and ipamorelin blend has no approval or bulks-list basis either. HHS's draft policy covers single-ingredient products only, so blends such as the Wolverine stack are not covered. [32]

Retatrutide is a special case. It is an investigational drug in phase 3 trials, not approved, and not compoundable, and FDA has warned about unapproved GLP-1 products sold online, retatrutide among them. [13] The lawful routes are a clinical trial, which you can search on ClinicalTrials.gov, or FDA expanded access, which is meant for people with serious conditions who cannot join a trial. [14] [15] Our guide on how to get retatrutide walks through both.

Can you get peptides prescribed online through telehealth?

Yes, for lawful products. The prescriber must be licensed in the state where you are located at the time of the visit. The federal rule requiring an in-person evaluation before prescribing controlled substances over the internet applies to controlled substances; the peptide drugs discussed here are not in that group. [16] Each state then sets its own rules for creating a valid telehealth relationship. Texas, for example, lists the methods that qualify, including synchronous audio-video visits. [17] Our Texas guide and the other state legal guides cover the details.

How to get peptides for weight loss

The lawful and best-studied options are the approved GLP-1 drugs, prescribed by a licensed clinician in person or by telehealth and filled at a licensed pharmacy. [2] [3] Routine compounded copies of semaglutide and tirzepatide ended when their shortages did; see our compounded tirzepatide guide. The GLP-1 hub collects prices and state access, the obesity condition page grades each option, and our weight loss ranking orders them by human evidence.

How to get peptides for muscle growth

No peptide is FDA approved to build muscle in healthy adults. Tesamorelin is approved to reduce abdominal fat in a specific HIV population, not to add muscle. [1] The growth hormone secretagogues sold for muscle, such as CJC-1295 and ipamorelin, are not approved and are not on the 503A bulks list, and growth-hormone-releasing peptides are prohibited in sport under WADA section S2. [18] Our muscle growth ranking and does tesamorelin build muscle cover the evidence.

What a legitimate peptide visit includes

A lawful prescription looks like ordinary medical care:

  1. A real evaluation. History, current medications, and the contraindications on the label, such as the boxed thyroid tumor warning on GLP-1 drugs. [2]
  2. A named product and pharmacy. You should know whether you are getting an approved drug or a compounded one, and which licensed pharmacy fills it. [6]
  3. A reason for compounding, if used. For copies of approved drugs, federal law requires a change that makes a significant difference for you. [5]
  4. A plan for monitoring and follow-up, including what to do about side effects.

Where to get peptide therapy: checking the pharmacy

Ask for the dispensing pharmacy's name and look up its license with your state board of pharmacy, including a nonresident license if it ships across state lines. FDA's BeSafeRx campaign lists the basics: a legitimate online pharmacy requires a prescription, is licensed in your state, and has a licensed pharmacist to answer questions. [19] Our provider verification guide explains how we check listings.

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers do offer many of the peptides in the groups above, and prescribers write prescriptions for them. That does not change the legal facts: FDA has proposed no rule for BPC-157 or the other five PCAC peptides, [10] and for those six, HHS's October 2026 draft policy only describes conditions under which it does not intend to take enforcement action. [32] Other peptides that are not approved and not on the 503A bulks list give a 503A pharmacy no federal basis to compound them from bulk. [7]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, its Category 2 safety list, and import alerts that let it detain peptide shipments, with a separate alert for GLP-1 bulk substances that names retatrutide, rather than stopping every pharmacy. [9] [21] [22] [23] [24] State boards of pharmacy oversee pharmacies day to day, and their rules differ. [6] [25] State boards can act. In August 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved. [27] Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [28]

What changes for you:

  • No FDA review of the product. FDA does not verify a compounded drug's safety, effectiveness, or quality before it is sold. [6]
  • Identity, purity, sterility, and dose accuracy vary. FDA has cited impurities and immunogenicity risk for several of these peptides. [9]
  • Insurance rarely pays, because there is no approved indication to match, so you usually pay cash.
  • Sport. Most are prohibited for tested athletes on the WADA list. [18]

If you're going ahead anyway, look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. [29] Expect a real evaluation by a prescriber licensed in the state where you are, who tells you the drug is compounded and not FDA approved, rather than an online form, [5] [30] and ask for a certificate of analysis for the specific batch. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach; a research-use-only product has neither. These checks lower some risks, but they do not make a product compounded outside section 503A lawful or safe. Each peptide page lists questions to ask the prescriber and pharmacy, for example BPC-157. Where an approved option exists, choose it: tesamorelin as Egrifta WR, [1] approved GLP-1 drugs such as tirzepatide and semaglutide instead of retatrutide, [2] [3] and bremelanotide as Vyleesi for its approved use. [4]

Red flags: research use only and other warning signs

  • "Research use only" or "not for human consumption" labels. These are not prescription products, and FDA warns they may contain the wrong ingredient or dose. [13]
  • No prescriber, or a checkbox form in place of a visit.
  • Peptides that are neither approved nor on the 503A bulks list, sold as routine prescriptions. [7]
  • Stacks sold as protocols. No trial has tested the popular combinations.
  • Claims that a compounded product is "the same as" an approved brand. Compounded drugs are not approved generics. [6]

The lawful list is short today. The safest question to ask any program is simple: is this an approved drug, a lawfully compounded prescription, or neither?

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

Which peptides can a doctor legally prescribe?

Any FDA-approved peptide drug, for its labeled use or off label, such as tirzepatide, semaglutide, tesamorelin, or bremelanotide. A 503A pharmacy may also compound a peptide that is a component of an approved drug, has a USP monograph, or is on FDA's 503A bulks list. Peptides that meet none of those conditions are not eligible for 503A compounding. [1] [2] [5] [7]

Can I get BPC-157 prescribed?

Only under a draft HHS policy with strict conditions. On October 28, 2026, HHS said it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding single-ingredient BPC-157 on a patient-specific prescription, by an allowed route, from tested substance made by an FDA-registered manufacturer. BPC-157 is still not FDA approved or on the 503A bulks list, blends are not covered, and state law still applies. [7] [31] [32]

Can I get peptides prescribed online through telehealth?

Yes, for lawful products, if the prescriber is licensed in the state where you are located and follows that state's rules for establishing a patient relationship. The federal in-person rule for prescribing controlled substances online does not apply to the peptide drugs discussed here, which are not controlled substances. [16] [17]

How can I get retatrutide legally?

Only by enrolling in a clinical trial, or in rare cases through FDA expanded access for a serious condition. Retatrutide is not approved and cannot be compounded, and FDA has warned about unapproved GLP-1 products sold online. [13] [14] [15]

Are research use only peptides legal to use?

No. Products labeled for research use only or not for human consumption are not a prescription product, are not made for human use, and may contain the wrong ingredient or amount. [13]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]FDA prescribing information for Egrifta WR (tesamorelin) for injection, via DailyMedFDA
  2. [2]FDA prescribing information for Zepbound (tirzepatide) injection, via DailyMedFDA
  3. [3]FDA prescribing information for Wegovy (semaglutide) injection and tablets, via DailyMedFDA
  4. [4]FDA prescribing information for Vyleesi (bremelanotide injection), via DailyMedFDA
  5. [5]21 U.S.C. 353a, Pharmacy compounding (Office of the Law Revision Counsel)
  6. [6]FDA: Compounding and the FDA, questions and answersFDA
  7. [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list and Category 1, 2, and 3 lists)FDA
  8. [8]Federal Register: List of bulk drug substances that can be used to compound drug products in accordance with section 503A (final rule, February 19, 2019)Federal Register, 2019
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 lists and withdrawn nominations, content current as of April 22, 2026)FDA, 2026
  10. [10]FDA: Pharmacy Compounding Advisory Committee (July 23 to 24, 2026 meeting on peptide nominations)FDA, 2026

More from the blog